ライフサイエンスコーパス: lasofoxifene

1 events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke.

2 The reduction in CHD events with lasofoxifene 0.25 mg/d was not significant (hazard ratio

3 o 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placeb

4 In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/d for 5 years reduced the risk of CH

5 asofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary

6 The effectiveness of lasofoxifene 0.5 mg/d in reducing CHD events was similar

7 D events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different cat

8 Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD even

9 ificant reduction in risk of CHD events with lasofoxifene 0.5 mg/d was due primarily to lower risks o

10 steoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years.

11 Lasofoxifene, a next-generation, oral, endocrine therapy

12 Lasofoxifene, a novel selective ER modulator, stabilizes

13 The lasofoxifene-abemaciclib combination was well tolerated

14 Lasofoxifene and arzoxifene are two newer SERMs that hav

15 Two newer drugs in this class, lasofoxifene and arzoxifene, also show efficacy and poss

16 ERD-1233 was developed based on Lasofoxifene as the ER binding moiety and a novel cerebl

17 d ratios were <1.0, no significant effect of lasofoxifene at 0.5 mg/d was demonstrated for coronary d

18 Lasofoxifene at a dose of 0.25 mg per day, as compared w

19 In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated

20 Lasofoxifene at a dose of 0.5 mg per day, as compared wi

21 femoral neck or spine to receive once-daily lasofoxifene (at a dose of either 0.25 mg or 0.5 mg) or

22 other clinical endpoints numerically favored lasofoxifene: clinical benefit rate (36.5% versus 21.6%;

23 Observed decreases in ESR1-mutant ctDNA with lasofoxifene concordant with clinical response suggest t

24 Lasofoxifene demonstrated encouraging antitumor activity

25 e most current efficacy analysis showed that lasofoxifene did not significantly prolong median PFS co

26 entified: tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, and anastrozole.

27 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxif

28 e placebo group, two women in the lower-dose lasofoxifene group, and two women in the higher-dose las

29 fene group, and two women in the higher-dose lasofoxifene group.

30 sofoxifene group, and 5.7 in the higher-dose lasofoxifene group.

31 Both doses of lasofoxifene increased the risk of venous thromboembolic

32 novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary

33 ty, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug

34 Lasofoxifene may be a promising targeted treatment for p

35 A total of 103 patients received lasofoxifene (n = 52) or fulvestrant (n = 51).

36 The effects of lasofoxifene on the risk of fractures, breast cancer, an

37 enopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxife

38 Lasofoxifene plus abemaciclib had an acceptable safety p

39 Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent t

40 ve estrogen receptor modulators, raloxifene, lasofoxifene, tamoxifen, bazedoxifene, or control vehicl

41 [13.2% (including a complete response in one lasofoxifene-treated patient) versus 2.9%; P = 0.124], a

42 rom baseline to week 8 in 82.9% of evaluable lasofoxifene-treated versus 61.5% of fulvestrant-treated

43 ommon treatment-emergent adverse events with lasofoxifene were nausea, fatigue, arthralgia, and hot f

44 ERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo, or in one study with tamoxif